The purpose of this analysis was to develop a population pharmacokinetic model for CS-917, an oral hypoglycemic prodrug, and its 3 metabolites. The population pharmacokinetic model was used to predict exposure of the active moiety R-125338 and thus to identify potential CS-917 dosage reduction criteria.
March 1, 2012
Author(s): Helen Kastrissios, Joseph Walker, Timothy Carrothers, Smita Kshirsagar, Tatiana Khariton, Bahru Habtemariam, Don Mager, Shashank Rohatagi
Year: March 1, 2012